Nyxoah Initiates Search for US-Based CEO to Accelerate Genio Launch
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
Category: Neurostimulators
Neurostimulators
Latest
Neurostimulators
Latest
First US Commercial Patients Implanted with Genio System
Physicians show ‘strong demand’ for the neurostimulator for obstructive sleep apnea patients, says Nyxoah CEO.
Neurostimulators
Latest
Inspire V on Track for Full Launch in 2025
The next-generation neurostimulator from Inspire Medical Systems will reduce surgical time and complexity.
Inspire Therapy Alternative Starting Electrode Configuration Improves OSA Less Than 8 Weeks Post-Activation
A sleep physician shares a case report of how a patient with severe sleep apnea achieved objective and subjective improvements more quickly with Inspire Therapy than via the standard activation and titration protocols.
Read More
How to Reduce the Time to Treatment for Patients Getting Sleep Apnea Neurostimulators
From candidacy to implantation to nightly use, the neurostimulator startup process is inherently lengthy. Sleep specialists can explore ways—from practical to novel—to make the process more efficient.
Read More
eXciteOSA Achieves European Union Medical Device Regulation Certification
According to Signifier, the EU MDR certification paves the way for broader adoption of eXciteOSA across European markets, enhancing accessibility.
Read More
Nyxoah Named Small Company of the Year at Euronext Brussels Awards
The maker of the Genio neurostimulator for obstructive sleep apnea received top honors in the gold category as Small Company of the Year, recognizing its excellence in Belgian capital markets.
Read More
Inspire Announces Revenue Gains and Organizational Changes
The company reported a 28% revenue increase for 2024 and unveiled new leadership roles.
Read More
Nyxoah’s Genio Neurostimulator for OSA Launches in England
The launch is marked by the first successful patient implants at University College London Hospitals.
Read More
Investigational Neurostimulator for OSA Cuts AHI By 66%
Topline clinical trial results demonstrate a 66.2% reduction in apnea-hypopnea index and a 63% reduction in oxygen desaturation after six months of therapy.
Read More
Nyxoah Posts Strong Q3 Results, Gears Up for Genio’s Anticipated US Launch
Nyxoah reports 30% sales growth and secures €24.6 million to support its anticipated US launch of the Genio neurostimulation system.
Read More
Inspire Reports 33% Year-over-Year Revenue Growth
In its Q3 results, Inspire Medical recapped highlights, including expanded therapy centers, FDA approval for its latest device, and publication of long-term safety data.
Read More
Texas Surgeon Marks 100th Inspire Sleep Apnea Device Implant
The milestone was achieved at a Lubbock, Texas, ambulatory surgery center.
Read More
Genio Neurostimulator Reduces AHI in Supine and Non-Supine Positions
Additional clinical data on patients with obstructive sleep apnea demonstrate a 71% median reduction in AHI while sleeping supine at 12 months compared with baseline.
Read More
Nyxoah Rings Nasdaq Closing Bell as It Prepares for Genio’s Expected US Launch
Nyxoah marked its recent milestones by ringing the Nasdaq Closing Bell, symbolizing the company’s forward momentum as it approaches the potential US market launch of its Genio device for OSA.
Read More
Long Beach Hospital Introduces Inspire for Children with Down Syndrome and OSA
The hospital completed its first two pediatric Inspire procedures.
Read More
Genio Neurostimulator Maker Gears Up for Anticipated US Market Entry
Nyxoah SA prepares for potential US approval of its Genio neurostimulator system for obstructive sleep apnea, with FDA submission complete and a decision expected by the end of 2024.
Read More
Inspire Expands Reach with New Approvals and Operational Growth
Inspire Medical Systems reported key regulatory approvals and operational expansions in the second quarter of 2024.
Read More